Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Financings Routine +

Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

Nxera Pharma Secures $22.5M Neurocrine Milestone Amidst Cash Burn Concerns

By The Northwire Desk — AI Analysis Apr 12, 2026 · 19:30 4565
Executive Summary
  • On April 12, 2026, Nxera Pharma announced that its partner Neurocrine Biosciences has dosed the first patient in a Phase 2 trial for NBI-1117570 (schizophrenia).
  • This event triggers a US$22.5 million milestone payment from Neurocrine to Nxera.
  • The revenue will be recognized in Q1 FY2026.
  • The trial is double-blind, placebo-controlled, enrolling ~120 adult patients with the primary endpoint being change in PANSS total score.
  • This follows a pattern of recent milestone achievements from partners including Eli Lilly (April 8), Centessa Pharmaceuticals (February/March), and AbbVie (October).
Material Impact
  • Cash Flow Impact: The US$22.5 million payment provides immediate liquidity. Given the FY2025 net loss of US$83.7 million and cash balance of US$130.2 million at Dec 31, 2025, this single milestone covers approximately 27% of the previous year's net loss or roughly 3 months of burn rate.
  • Validation: Confirms the viability of the NxWave platform in generating partner-funded clinical progress (second compound from platform to reach Phase 2 with Neurocrine).
  • Expectation vs. Reality: While positive, this is consistent with the existing collaboration agreement terms where Phase 2 initiation triggers payments. It does not represent a new partnership or unexpected breakthrough but rather execution of known milestones.
  • Risk Mitigation: Helps extend cash runway slightly but does not fundamentally alter the structural deficit where R&D and SG&A expenses exceed product revenue (FY2025 Revenue US$197.9M vs Operating Loss US$56.5M).
4565 · Price
Company Overview
  • Overview: Nxera Pharma is a biopharmaceutical company focused on GPCR-targeted drug discovery using its proprietary NxWave platform. It operates through partnerships (Neurocrine, Lilly, Centessa) and commercializes products like daridorexant (QUVIVIQ) in specific territories.
  • Flagship Commercial Product: Daridorexant (QUVIVIQ), a dual orexin receptor antagonist for insomnia. Approved in Japan (partnered with Shionogi), US/EU (Idorsia), China/HK (Simcere). South Korea MAA submitted March 2026.
  • Flagship Pipeline: NBI-1117570 (Schizophrenia, Phase 2 with Neurocrine), ORX agonists (Metabolic/Neuro, with Centessa/Lilly), and proprietary obesity/metabolic pipeline launched late 2025.
Read the original news release →

More from

Jun 30, 2026 · 04:27

AI-driven GPCR drug discovery platform monetizing partnerships while transitioning to a profitable specialty pharma model in APAC.

Other Jun 10, 2026 · 02:35

AI-driven GPCR drug discovery platform accelerates pipeline through strategic consortium membership and milestone-driven revenue turnaround.

M&A / Property Jun 01, 2026 · 19:30

Nxera Accelerates Vamorolone Rollout in South Korea as APAC Specialty Pharma Strategy Gains Traction

Regulatory May 11, 2026 · 02:34

GPCR spin-out reels in $275M in biobucks and equity, keeping Asia rights and cash burn in check

M&A / Property May 08, 2026 · 06:26

Nxera Pharma Defends Core IP Amidst Profitability Turnaround

Regulatory May 01, 2026 · 02:36

Nxera Pharma Turns Profitable on Milestone Surge, But Cash Burn Raises Liquidity Questions

Earnings